Review



secure web-based randomisation program  (MedSciNet UK Ltd)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    MedSciNet UK Ltd secure web-based randomisation program
    Maternal demographic and pregnancy characteristics at baseline and <t> randomisation </t>
    Secure Web Based Randomisation Program, supplied by MedSciNet UK Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/randomisation/secure+computerised+randomisation+system/pmc06892281-190-5-11
    Average 90 stars, based on 1 article reviews
    secure web-based randomisation program - by Bioz Stars, 2026-10
    90/100 stars

    Images

    1) Product Images from "Planned early delivery or expectant management for late preterm pre-eclampsia (PHOENIX): a randomised controlled trial"

    Article Title: Planned early delivery or expectant management for late preterm pre-eclampsia (PHOENIX): a randomised controlled trial

    Journal: Lancet (London, England)

    doi: 10.1016/S0140-6736(19)31963-4

    Maternal demographic and pregnancy characteristics at baseline and randomisation
    Figure Legend Snippet: Maternal demographic and pregnancy characteristics at baseline and randomisation

    Techniques Used:

    Related Articles

    other:

    Article Title: Prophylactic exchange-transfusion in sickle cell disease pregnancy: TAPS2 feasibility randomized controlled trial.
    Article Snippet: Participants were allocated in a ratio of 1:1 to intervention and control arm; randomization was performed using a web-based randomization system (MedSciNet), minimizing on center, SCD genotype and maternal age.

    Article Title: Placental growth fActor Repeat sampling for Reduction of adverse perinatal Outcomes in women with suspecTed pre-eclampsia: study protocol for a randomised controlled trial (PARROT-2)
    Article Snippet: The MedSciNet web-based randomisation, using a minimisation algorithm as described above, will ensure that the mechanism for deriving the allocation is not shared with researchers, clinicians, and participants.

    Article Title: Two‐year follow‐up of infant and maternal outcomes after planned early delivery or expectant management for late preterm pre‐eclampsia ( PHOENIX ): A randomised controlled trial
    Article Snippet: The only exclusion criterion to participation was the clinician’s decision to initiate delivery within the subsequent 48 h. After providing written informed consent, women were randomly assigned to planned delivery or expectant management via a secure web‐based randomisation program provided by MedSciNet.

    Article Title: Planned delivery or expectant management for late preterm pre-eclampsia in low-income and middle-income countries (CRADLE-4): a multicentre, open-label, randomised controlled trial
    Article Snippet: Participants were recruited from nine hospitals and referral facilities in India and Zambia and randomly assigned to planned delivery or expectant management in a 1:1 ratio by a secure web-based randomisation facility hosted by MedSciNet.

    Article Title: Prophylactic exchange transfusion in sickle cell disease pregnancy: a TAPS2 feasibility randomized controlled trial
    Article Snippet: Participants were allocated in a ratio of 1:1 to intervention and control arm; randomization was performed using a web-based randomization system (MedSciNet), minimizing on center, SCD genotype, and maternal age.

    Sequencing:

    Article Title: A community-based mentoring scheme for pregnant and parenting adolescents in Sierra Leone: Protocol for a hybrid pilot cluster randomised controlled trial
    Article Snippet: .. The clusters will be first allocated random cluster numbers and the sequence generation for receiving the 2YL intervention will then be determined by computer-generated random numbers by the trial statistician via a secure web-based randomisation and data management system hosted by MedSciNet with telephone back-up available at all times. ..

    Article Title: Midwife continuity of care models versus other models of care for childbearing women
    Article Snippet: .. Random sequence generation (selection bias) , Low risk , Random assignment in a ratio of 1:1 via a secure computerised randomisation system (MedSciNet). They also used a minimisation algorithm with a random element to ensure balanced groups regarding previous PTB and smoking at booking.. .. Allocation concealment (selection bias) , Low risk , Central randomisation and use of a "secure system" ‐ contacted author team for clarification: "Research assistant and all midwives logged in to the database, added a participant and baseline information, confirmed eligibility and consent form, and then clicked the bottom 'randomise' ‐ then the MEdscinet program told us if the woman was allocated to standard care or poppie (there was no way we could know what the woman was going to be allocated to, neither the following women)"..

    Selection:

    Article Title: Midwife continuity of care models versus other models of care for childbearing women
    Article Snippet: .. Random sequence generation (selection bias) , Low risk , Random assignment in a ratio of 1:1 via a secure computerised randomisation system (MedSciNet). They also used a minimisation algorithm with a random element to ensure balanced groups regarding previous PTB and smoking at booking.. .. Allocation concealment (selection bias) , Low risk , Central randomisation and use of a "secure system" ‐ contacted author team for clarification: "Research assistant and all midwives logged in to the database, added a participant and baseline information, confirmed eligibility and consent form, and then clicked the bottom 'randomise' ‐ then the MEdscinet program told us if the woman was allocated to standard care or poppie (there was no way we could know what the woman was going to be allocated to, neither the following women)"..



    Similar Products

    pre randomisation tumour specimen  (Foundation Medicine Inc)
    99
    Foundation Medicine Inc pre randomisation tumour specimen
    Pre Randomisation Tumour Specimen, supplied by Foundation Medicine Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/randomisation/FoundationOne+CDx/pm41422862-70-13-20
    Average 99 stars, based on 1 article reviews
    pre randomisation tumour specimen - by Bioz Stars, 2026-10
    99/100 stars
    		  Buy from Supplier
    randomisation list  (Minitab Inc)
    86
    Minitab Inc randomisation list
    Randomisation List, supplied by Minitab Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/randomisation/computer+generated+list+randomization/pmc13055410-68-35-38
    Average 86 stars, based on 1 article reviews
    randomisation list - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    gcp compliant randomisation system  (Tayside Pharmaceuticals)
    86
    Tayside Pharmaceuticals gcp compliant randomisation system
    AIR-NET adaptive platform trial design summary . The AIR-NET randomised, open-label, multifactorial, multicentre adaptive platform trial has a parallel group design; the trial will open to recruitment with a control arm and the first three treatment arms indicated (oral dose: disulfiram 400 mg once daily; dipyridamole 200 mg twice daily; doxycycline 100 mg once daily. n=42/arm). All three drugs were chosen for their published anti-inflammatory and neutrophil modulatory activities, wide availability, and acceptable safety profiles. Potential participants will be screened for generic eligibility criteria, positive sputum neutrophil elastase lateral flow test and according to arm-specific criteria. Participants will receive 28 days treatment, with a further post-treatment follow-up at day 56. Individual treatment arms will be closed for <t>randomisation</t> when the target for number of participants has been reached, or earlier if advised by the data monitoring committee and closed to follow-up after last participant last visit for that arm. As new possibilities for treatments are identified additional treatment arms will be opened. Any new treatment arms will be submitted as an amendment to the current protocol. Randomisation to the control arm will continue for the duration of the trial. The primary outcome is change from baseline in sputum neutrophil elastase activity, analysis will be performed by pairwise comparison of each treatment arm to concurrent usual care participants, with analysis times varying by arm according to respective last participant last visit.
    Gcp Compliant Randomisation System, supplied by Tayside Pharmaceuticals, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/randomisation/compliant+gcp+randomisation+system/pmc12969703-132-9-12
    Average 86 stars, based on 1 article reviews
    gcp compliant randomisation system - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    randomisation  (STATA Corporation)
    99
    STATA Corporation randomisation
    AIR-NET adaptive platform trial design summary . The AIR-NET randomised, open-label, multifactorial, multicentre adaptive platform trial has a parallel group design; the trial will open to recruitment with a control arm and the first three treatment arms indicated (oral dose: disulfiram 400 mg once daily; dipyridamole 200 mg twice daily; doxycycline 100 mg once daily. n=42/arm). All three drugs were chosen for their published anti-inflammatory and neutrophil modulatory activities, wide availability, and acceptable safety profiles. Potential participants will be screened for generic eligibility criteria, positive sputum neutrophil elastase lateral flow test and according to arm-specific criteria. Participants will receive 28 days treatment, with a further post-treatment follow-up at day 56. Individual treatment arms will be closed for <t>randomisation</t> when the target for number of participants has been reached, or earlier if advised by the data monitoring committee and closed to follow-up after last participant last visit for that arm. As new possibilities for treatments are identified additional treatment arms will be opened. Any new treatment arms will be submitted as an amendment to the current protocol. Randomisation to the control arm will continue for the duration of the trial. The primary outcome is change from baseline in sputum neutrophil elastase activity, analysis will be performed by pairwise comparison of each treatment arm to concurrent usual care participants, with analysis times varying by arm according to respective last participant last visit.
    Randomisation, supplied by STATA Corporation, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/randomisation/STATA+12%2E0/pmc12960068-56-0-4
    Average 99 stars, based on 1 article reviews
    randomisation - by Bioz Stars, 2026-10
    99/100 stars
    		  Buy from Supplier
    randomisation sequence  (STATA Corporation)
    99
    STATA Corporation randomisation sequence
    AIR-NET adaptive platform trial design summary . The AIR-NET randomised, open-label, multifactorial, multicentre adaptive platform trial has a parallel group design; the trial will open to recruitment with a control arm and the first three treatment arms indicated (oral dose: disulfiram 400 mg once daily; dipyridamole 200 mg twice daily; doxycycline 100 mg once daily. n=42/arm). All three drugs were chosen for their published anti-inflammatory and neutrophil modulatory activities, wide availability, and acceptable safety profiles. Potential participants will be screened for generic eligibility criteria, positive sputum neutrophil elastase lateral flow test and according to arm-specific criteria. Participants will receive 28 days treatment, with a further post-treatment follow-up at day 56. Individual treatment arms will be closed for <t>randomisation</t> when the target for number of participants has been reached, or earlier if advised by the data monitoring committee and closed to follow-up after last participant last visit for that arm. As new possibilities for treatments are identified additional treatment arms will be opened. Any new treatment arms will be submitted as an amendment to the current protocol. Randomisation to the control arm will continue for the duration of the trial. The primary outcome is change from baseline in sputum neutrophil elastase activity, analysis will be performed by pairwise comparison of each treatment arm to concurrent usual care participants, with analysis times varying by arm according to respective last participant last visit.
    Randomisation Sequence, supplied by STATA Corporation, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/randomisation/STATA+15%2E0/pm41549406-39-1-6
    Average 99 stars, based on 1 article reviews
    randomisation sequence - by Bioz Stars, 2026-10
    99/100 stars
    		  Buy from Supplier
    randomisation list  (Novartis)
    86
    Novartis randomisation list
    AIR-NET adaptive platform trial design summary . The AIR-NET randomised, open-label, multifactorial, multicentre adaptive platform trial has a parallel group design; the trial will open to recruitment with a control arm and the first three treatment arms indicated (oral dose: disulfiram 400 mg once daily; dipyridamole 200 mg twice daily; doxycycline 100 mg once daily. n=42/arm). All three drugs were chosen for their published anti-inflammatory and neutrophil modulatory activities, wide availability, and acceptable safety profiles. Potential participants will be screened for generic eligibility criteria, positive sputum neutrophil elastase lateral flow test and according to arm-specific criteria. Participants will receive 28 days treatment, with a further post-treatment follow-up at day 56. Individual treatment arms will be closed for <t>randomisation</t> when the target for number of participants has been reached, or earlier if advised by the data monitoring committee and closed to follow-up after last participant last visit for that arm. As new possibilities for treatments are identified additional treatment arms will be opened. Any new treatment arms will be submitted as an amendment to the current protocol. Randomisation to the control arm will continue for the duration of the trial. The primary outcome is change from baseline in sputum neutrophil elastase activity, analysis will be performed by pairwise comparison of each treatment arm to concurrent usual care participants, with analysis times varying by arm according to respective last participant last visit.
    Randomisation List, supplied by Novartis, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/randomisation/list+randomisation/10__1002_slash_14651858__cd009885__pub4-5010-38-10
    Average 86 stars, based on 1 article reviews
    randomisation list - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    tayside randomisation system trust  (Tayside Pharmaceuticals)
    86
    Tayside Pharmaceuticals tayside randomisation system trust
    AIR-NET adaptive platform trial design summary . The AIR-NET randomised, open-label, multifactorial, multicentre adaptive platform trial has a parallel group design; the trial will open to recruitment with a control arm and the first three treatment arms indicated (oral dose: disulfiram 400 mg once daily; dipyridamole 200 mg twice daily; doxycycline 100 mg once daily. n=42/arm). All three drugs were chosen for their published anti-inflammatory and neutrophil modulatory activities, wide availability, and acceptable safety profiles. Potential participants will be screened for generic eligibility criteria, positive sputum neutrophil elastase lateral flow test and according to arm-specific criteria. Participants will receive 28 days treatment, with a further post-treatment follow-up at day 56. Individual treatment arms will be closed for <t>randomisation</t> when the target for number of participants has been reached, or earlier if advised by the data monitoring committee and closed to follow-up after last participant last visit for that arm. As new possibilities for treatments are identified additional treatment arms will be opened. Any new treatment arms will be submitted as an amendment to the current protocol. Randomisation to the control arm will continue for the duration of the trial. The primary outcome is change from baseline in sputum neutrophil elastase activity, analysis will be performed by pairwise comparison of each treatment arm to concurrent usual care participants, with analysis times varying by arm according to respective last participant last visit.
    Tayside Randomisation System Trust, supplied by Tayside Pharmaceuticals, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/randomisation/compliant+gcp+randomisation+system/10__1183_slash_23120541__00719___2025-296-236-236
    Average 86 stars, based on 1 article reviews
    tayside randomisation system trust - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    randomisation system  (Tayside Pharmaceuticals)
    86
    Tayside Pharmaceuticals randomisation system
    AIR-NET adaptive platform trial design summary . The AIR-NET randomised, open-label, multifactorial, multicentre adaptive platform trial has a parallel group design; the trial will open to recruitment with a control arm and the first three treatment arms indicated (oral dose: disulfiram 400 mg once daily; dipyridamole 200 mg twice daily; doxycycline 100 mg once daily. n=42/arm). All three drugs were chosen for their published anti-inflammatory and neutrophil modulatory activities, wide availability, and acceptable safety profiles. Potential participants will be screened for generic eligibility criteria, positive sputum neutrophil elastase lateral flow test and according to arm-specific criteria. Participants will receive 28 days treatment, with a further post-treatment follow-up at day 56. Individual treatment arms will be closed for <t>randomisation</t> when the target for number of participants has been reached, or earlier if advised by the data monitoring committee and closed to follow-up after last participant last visit for that arm. As new possibilities for treatments are identified additional treatment arms will be opened. Any new treatment arms will be submitted as an amendment to the current protocol. Randomisation to the control arm will continue for the duration of the trial. The primary outcome is change from baseline in sputum neutrophil elastase activity, analysis will be performed by pairwise comparison of each treatment arm to concurrent usual care participants, with analysis times varying by arm according to respective last participant last visit.
    Randomisation System, supplied by Tayside Pharmaceuticals, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/randomisation/compliant+gcp+randomisation+system/10__1183_slash_23120541__00719___2025-209-12-14
    Average 86 stars, based on 1 article reviews
    randomisation system - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    � fsc corrected fsc unmasked fsc masked fsc phase randomised 0 75xk10 peg pbs b dc  (Thermo Fisher)
    99
    Thermo Fisher � fsc corrected fsc unmasked fsc masked fsc phase randomised 0 75xk10 peg pbs b dc
    AIR-NET adaptive platform trial design summary . The AIR-NET randomised, open-label, multifactorial, multicentre adaptive platform trial has a parallel group design; the trial will open to recruitment with a control arm and the first three treatment arms indicated (oral dose: disulfiram 400 mg once daily; dipyridamole 200 mg twice daily; doxycycline 100 mg once daily. n=42/arm). All three drugs were chosen for their published anti-inflammatory and neutrophil modulatory activities, wide availability, and acceptable safety profiles. Potential participants will be screened for generic eligibility criteria, positive sputum neutrophil elastase lateral flow test and according to arm-specific criteria. Participants will receive 28 days treatment, with a further post-treatment follow-up at day 56. Individual treatment arms will be closed for <t>randomisation</t> when the target for number of participants has been reached, or earlier if advised by the data monitoring committee and closed to follow-up after last participant last visit for that arm. As new possibilities for treatments are identified additional treatment arms will be opened. Any new treatment arms will be submitted as an amendment to the current protocol. Randomisation to the control arm will continue for the duration of the trial. The primary outcome is change from baseline in sputum neutrophil elastase activity, analysis will be performed by pairwise comparison of each treatment arm to concurrent usual care participants, with analysis times varying by arm according to respective last participant last visit.
    � Fsc Corrected Fsc Unmasked Fsc Masked Fsc Phase Randomised 0 75xk10 Peg Pbs B Dc, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/randomisation/PHOSPHATE+BUFFERED+SALINE+PBS/pm33724780__nn0c10137_si_001-14-69-109
    Average 99 stars, based on 1 article reviews
    � fsc corrected fsc unmasked fsc masked fsc phase randomised 0 75xk10 peg pbs b dc - by Bioz Stars, 2026-10
    99/100 stars
    		  Buy from Supplier

    Image Search Results


    AIR-NET adaptive platform trial design summary . The AIR-NET randomised, open-label, multifactorial, multicentre adaptive platform trial has a parallel group design; the trial will open to recruitment with a control arm and the first three treatment arms indicated (oral dose: disulfiram 400 mg once daily; dipyridamole 200 mg twice daily; doxycycline 100 mg once daily. n=42/arm). All three drugs were chosen for their published anti-inflammatory and neutrophil modulatory activities, wide availability, and acceptable safety profiles. Potential participants will be screened for generic eligibility criteria, positive sputum neutrophil elastase lateral flow test and according to arm-specific criteria. Participants will receive 28 days treatment, with a further post-treatment follow-up at day 56. Individual treatment arms will be closed for randomisation when the target for number of participants has been reached, or earlier if advised by the data monitoring committee and closed to follow-up after last participant last visit for that arm. As new possibilities for treatments are identified additional treatment arms will be opened. Any new treatment arms will be submitted as an amendment to the current protocol. Randomisation to the control arm will continue for the duration of the trial. The primary outcome is change from baseline in sputum neutrophil elastase activity, analysis will be performed by pairwise comparison of each treatment arm to concurrent usual care participants, with analysis times varying by arm according to respective last participant last visit.

    Journal: ERJ Open Research

    Article Title: Design and rationale of the AIR-NET trial: a randomised, open-label, multifactorial, multicentre, adaptive platform trial using a range of repurposed anti-inflammatory treatments to improve outcomes in patients with bronchiectasis within the EMBARC clinical research network

    doi: 10.1183/23120541.00719-2025

    Figure Lengend Snippet: AIR-NET adaptive platform trial design summary . The AIR-NET randomised, open-label, multifactorial, multicentre adaptive platform trial has a parallel group design; the trial will open to recruitment with a control arm and the first three treatment arms indicated (oral dose: disulfiram 400 mg once daily; dipyridamole 200 mg twice daily; doxycycline 100 mg once daily. n=42/arm). All three drugs were chosen for their published anti-inflammatory and neutrophil modulatory activities, wide availability, and acceptable safety profiles. Potential participants will be screened for generic eligibility criteria, positive sputum neutrophil elastase lateral flow test and according to arm-specific criteria. Participants will receive 28 days treatment, with a further post-treatment follow-up at day 56. Individual treatment arms will be closed for randomisation when the target for number of participants has been reached, or earlier if advised by the data monitoring committee and closed to follow-up after last participant last visit for that arm. As new possibilities for treatments are identified additional treatment arms will be opened. Any new treatment arms will be submitted as an amendment to the current protocol. Randomisation to the control arm will continue for the duration of the trial. The primary outcome is change from baseline in sputum neutrophil elastase activity, analysis will be performed by pairwise comparison of each treatment arm to concurrent usual care participants, with analysis times varying by arm according to respective last participant last visit.

    Article Snippet: Randomisation will be done via the centrally controlled, web-based, GCP-compliant randomisation system, Tayside Randomisation System (TRuST), run by the Health Informatics Centre (University of Dundee), with allocation provided via email.

    Techniques: Control, Activity Assay, Comparison